| Code | CSB-MP012145HU |
| Abbreviation | Recombinant Human KDR protein, partial (Active) |
| MSDS | |
| Size | $114 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
VEGFR-2 mediates the majority of VEGF-driven angiogenic signaling in both physiological and pathological contexts, making quantitative assessment of ligand-receptor interactions central to cancer biology and therapeutic development. This mammalian-expressed extracellular domain (aa 20–764) binds immobilized human VEGF-A with an EC50 of 11.19–12.63 ng/mL in functional ELISA, providing a validated reagent for competitive inhibition assays that screen anti-angiogenic antibodies or small-molecule antagonists targeting the VEGF-VEGFR-2 axis. The C-terminal hFc1 tag enables straightforward immobilization in surface plasmon resonance and biolayer interferometry platforms, supporting affinity characterization and epitope mapping studies for therapeutic antibody candidates. With purity exceeding 95% by SDS-PAGE and endotoxin below 1.0 EU/μg, this protein meets the quality thresholds commonly required for ligand-binding assays and serves as a positive control in drug discovery workflows focused on angiogenesis inhibition.
There are currently no reviews for this product.